<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292886</url>
  </required_header>
  <id_info>
    <org_study_id>NanjingU</org_study_id>
    <nct_id>NCT04292886</nct_id>
  </id_info>
  <brief_title>Thin Endometrium Undergoing Frozen-thawed Embryo Transfer</brief_title>
  <official_title>Hormone Replacement Versus Tamoxifen Combined Of Hormone Replacement in Women With a Thin Endometrium Undergoing Frozen-thawed Embryo Transfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The endometrium is essential for embryo implantation. The clinical pregnancy rate and live
      birth rate of patients with thin endometrium are significantly lower than those of normal
      endometrium. Previous studies have shown that tamoxifen has advantages for improving
      endometrial thickness. However, there is still a lack of evidence from randomized clinical
      trials comparing the efficacy between hormone replacement and Tamoxifen combined Of hormone
      replacement.This is a prospective, randomized placebo-controlled, double-blind clinical trial
      that includes 120 patients younger than 38 years old with a thin endometrium preparing for
      frozen embryo transfer. Participants will be randomly assigned (1: 1) into two parallel
      groups: estrogen replacement and tamoxifen combined with estrogen replacement.Frozen embryo
      resuscitation transfer cycle for thin endometrium patients。This is the first randomized
      controlled trial to comparing estrogen and estrogen combined with tamoxifen for endometrial
      improvement，The results of this study will provide evidence for the efficacy of the strategy
      of frozen embryo transfer cycle for thin endometrium patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>within the 15 days (plus or minus 5 days) after oral drugs</time_frame>
    <description>Endometrial thickness were record using transvaginal ultrasound scan.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thin Endometrium</condition>
  <arm_group>
    <arm_group_label>thin endometrium ,treatment,Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>From the 2nd day of the menstrual cycle, the patient took tamoxifen and femoston</description>
  </arm_group>
  <arm_group>
    <arm_group_label>thin endometrium ,treatment,Vitamin C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>From the 2nd day of the menstrual cycle, the patient took Vitamin C and femoston</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen and femoston</intervention_name>
    <description>oral</description>
    <arm_group_label>thin endometrium ,treatment,Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C and femoston</intervention_name>
    <description>Vitamin C and femoston</description>
    <arm_group_label>thin endometrium ,treatment,Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Younger than 38 years old, basal serum level of follicle stimulating hormone &lt;10 IU / L;
        (2) Endometrium is less than 8mm in at least 2 cycles: superovulation cycle / natural cycle
        / estrogen replacement therapy / ovarian stimulation cycle; (3) at least 1 high quality
        frozen embryo; (4) There are no comorbidities that clearly affect pregnancy, such as
        adenomyosis, endometriosis, and intrauterine adhesions;

        Exclusion Criteria:

          1. abnormal karyotype;

          2. Accompanying other diseases of the uterus: uterine muscular wall myomas that affect
             the uterine cavity shape, more severe adenomyosis, severe endometriosis, congenital
             uterine malformations, endometrial tuberculosis, etc .;

          3. Contraindications to hormone replacement therapy;

          4. Participating in other clinical research;

          5. History of previous fundus diseases;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haixiang Sun, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qingqing Shi, Ph.D</last_name>
    <phone>15996312878</phone>
    <email>qqshnju@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingqing Shi, Ph.D</last_name>
      <email>qqshnju@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 1, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University</investigator_affiliation>
    <investigator_full_name>Li-jun Ding</investigator_full_name>
    <investigator_title>Qingqing Shi</investigator_title>
  </responsible_party>
  <keyword>thin endometrium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

